TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8737627
Drug: 0.250 mg
Normalized name: DIGOXIN 0.250 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.250 mg brotizolam
Study: 1521686
Drug: Indirect evaluation
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indirect evaluation using M‐L scale
Study: 28439987
Drug: Silodosin 8
Normalized name: silodosin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silodosin 8 mg/day
Study: 25546001
Drug: Tafamidis 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tafamidis 400 mg
Study: 16891338
Drug: Ethyl-eicosapentanoic acid
Normalized name: Eicosapentaenoic acid ethyl ester
DrugBank: Icosapent ethyl (DB08887)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ethyl-eicosapentanoic acid (ethyl-EPA) 2 g per day
Study: 11509461
Drug: Cognitive behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behaviour therapy (CBT) self-help programme; 6 months follow-up
Study: 9586828
Drug: Active medication
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active medication (beta-carotene 15 mg, vitamin C 150 mg, vitamin E 75 mg, selenium 101 microg, calcium 1.6 g daily)
Study: 7922794
Drug: rectal salmon
Approvals — FDA: no, EMA: no, PMDA: no
Description: rectal salmon calcitonin (sCT), 100 IU daily (n = 25)
Study: 7922794
Drug: nasal salmon
Approvals — FDA: no, EMA: no, PMDA: no
Description: nasal salmon calcitonin (sCT), 200 IU daily (n = 17)
Study: 7922794
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (18 age‐matched women who received no treatment)
Study: 3044871
Drug: Cefatrizine 75
Normalized name: cefatrizine
DrugBank: Cefatrizine (DB13266)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefatrizine 75 mg/kg.day once daily for 8 days
Study: 3044871
Drug: Cefatrizine 75
Normalized name: cefatrizine
DrugBank: Cefatrizine (DB13266)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefatrizine 75 mg/kg.day twice daily for 8 days
Study: 23829621
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) with house dust mite (HDM) extracts
Study: 11399214
Drug: Daily maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily maintenance doses of 4 mg/70 kg (n = 14) or 8 mg/70 kg (n = 19) of liquid buprenorphine
Study: 10962771
Drug: Triple the
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple the daily maintenance dose every 72 hours (12 or 24 mg/70 kg)
Study: 11399214
Drug: Quintuple the
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quintuple the daily maintenance dose every 120 hours (20 or 40 mg/70 kg)
Study: 11399214
Drug: Open-dosing procedures
Normalized name: BOTTLE OPENER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-dosing procedures with three dosing regimens
Study: 8381674
Drug: 7 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 g/day of a 85% n-3 fatty acid concentrate
Study: 3690030
Drug: Almitrine bismesylate
Normalized name: almitrine dimesylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almitrine bismesylate (1.5 mg.kg-1, orally twice a day for 14 days)
Study: 30849287
Drug: Individual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual therapy for 6 weeks
Study: 30849287
Drug: Group therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group therapy for 6 weeks
Study: 31099218
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (abdominal acupuncture + periodic therapy of Chinese herbal medicine)
Study: 31099218
Drug: Western medication
Normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medication (clomiphene citrate + human chorionic gonadotrophin)
Study: 25444222
Drug: Community consultation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community consultation and public disclosure (CC/PD) process using multimedia approach
Study: 25444222
Drug: Cost of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cost of the CC/PD process
Study: 25444222
Drug: Effectiveness of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Effectiveness of the CC/PD process
Study: 22010914
Drug: Earlier ART
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Earlier ART (within 2 weeks after the initiation of treatment for tuberculosis)
Study: 22010914
Drug: Later ART
Approvals — FDA: no, EMA: no, PMDA: no
Description: Later ART (between 8 and 12 weeks after the initiation of treatment for tuberculosis)
Study: 15080862
Drug: Subcutaneous apomorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous apomorphine injection
Study: 12584692
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (4 mg via 15-minute infusion)
Study: 9652613
Drug: Inactivated influenza
Normalized name: influenza, inactivated, whole virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated influenza vaccine (excluding participants with colds)
Study: 15383193
Drug: Trimetazidine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine (20 mg 3 times daily)
Study: 2111669
Drug: Intravenous Flecainide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Flecainide acetate (1.5 mg/kg over 5 minutes) - Group I
Study: 2111669
Drug: Intravenous Flecainide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Flecainide acetate (2 mg/kg over 5 minutes) - Group II
Study: 359779
Drug: Intramuscular oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular oxycodone
Study: 359779
Drug: Intramuscular codeine
Normalized name: Codeine
DrugBank: Codeine (DB00318)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular codeine
Study: 31232275
Drug: Umeclidinium (UMEC)
Normalized name: Umeclidinium
DrugBank: Umeclidinium (DB09076)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Umeclidinium (UMEC) 62.5 µg once-daily added to fluticasone furoate/vilanterol (FF/VI) 200/25 µg once-daily
Study: 21684715
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of autologous tissue repair cells (TRCs)
Study: 18332170
Drug: Amoxicillin sprinkle
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin sprinkle (475 mg for ages 6 months to 4 years, 775 mg for ages 5 to 12 years) QD for 7 days
Study: 18332170
Drug: Penicillin VK
Normalized name: PENICILLIN VK 250MG TAB
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin VK (10 mg/kg QID for 10 days, max 250 mg QID)
Study: 16823726
Drug: Vildagliptin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vildagliptin (25 mg, bid)
Study: 10994155
Drug: Trimebutine tablets
Normalized name: trimebutine
DrugBank: Trimebutine (DB09089)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimebutine tablets (100 mg)
Study: 10994155
Drug: New tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: New tablet formulation (Eurogalena, 100 mg)
Study: 8466376
Drug: Indwelling Teflon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indwelling Teflon catheter for heparin administration
Study: 8466376
Drug: Twice-daily subcutaneous
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily subcutaneous injections of heparin
Study: 24781223
Drug: EEG-BFB-therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: EEG-BFB-therapy
Study: 14748998
Drug: Methylprednisolone (MP)
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone (MP) plus cyclophosphamide (CPA) intermittent intravenous pulse therapy (Group A)
Study: 10744208
Drug: Injection speed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injection speed of 20 seconds (group A)
Study: 10744208
Drug: Injection speed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injection speed of 60 seconds (group B)
Study: 3304518
Drug: Supportive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive treatment only (Control)
Study: 29697830
Drug: Metformin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin with or without rosiglitazone, metformin plus lifestyle
Study: 22615787
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (bilateral BL2, GB14, TE 23, Ex1, ST1, GB20, LI4, LI11 and single GV23)
Study: 20839418
Drug: Topical steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical steroids (mometasone furoate) applied twice daily
Study: 20839418
Drug: Intralesional steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional steroids (triamcinolone acetonide) injected at monthly intervals (1 to 2 mg/kg)
Study: 20839418
Drug: Topical steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical steroids (mometasone furoate)
Study: 20839418
Drug: Intralesional steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional steroids (triamcinolone acetonide)
Study: 18257978
Drug: Indiplon 5
Normalized name: Indiplon
DrugBank: Indiplon (DB12590)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indiplon 5 mg
Study: 2725453
Drug: Zopiclone 3.75
Normalized name: zopiclone 3.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zopiclone 3.75 mg
Study: 2288825
Drug: Midazolam 15
Normalized name: midazolam 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 15 mg p.o.
Study: 2288825
Drug: Nitrazepam 5
Normalized name: nitrazepam 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrazepam 5 mg p.o.
Study: 6250699
Drug: Nabilone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nabilone (2 mg every 12 hours)
Study: 6250699
Drug: Prochlorperazine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prochlorperazine (10 mg every 12 hours)
Study: 23599623
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of normal saline and hydroxyethyl starch (HES) (SH group)
Study: 23599623
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of normal saline, hydroxyethyl starch and glutamine (SHG group)
Study: 11419611
Drug: Relaxation Response
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Relaxation Response Meditation (twice a day for 15 minutes for six weeks)
Study: 8275619
Drug: Diazepam 40
Normalized name: Diazepam 400 microgram/mL oral solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 40 mg
Study: 8275619
Drug: Pentobarbital 120
Normalized name: PENTobarbital 120 mg rectal suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentobarbital 120 mg
Study: 8275619
Drug: Pentobarbital 240
Normalized name: Pentobarbital
DrugBank: Pentobarbital (DB00312)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentobarbital 240 mg
Study: 27004531
Drug: Carbetocin 100
Normalized name: Carbetocin 100 microgram/mL solution for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbetocin 100 mcg as a slow intravenous bolus
Study: 27004531
Drug: Carbetocin 100
Normalized name: Carbetocin 100 microgram/mL solution for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbetocin 100 mcg as a short-infusion in 100 ml 0.9% sodium chloride
Study: 23511711
Drug: Midazolam (0.0001‐3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.0001‐3 mg)
Study: 20107296
Drug: Desvenlafaxine succinate
Normalized name: Desvenlafaxine Succinate
DrugBank: Desvenlafaxine (DB06700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desvenlafaxine succinate (DVS) 50 mg/day
Study: 20107296
Drug: Desvenlafaxine succinate
Normalized name: Desvenlafaxine Succinate
DrugBank: Desvenlafaxine (DB06700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desvenlafaxine succinate (DVS) > 50 mg/day
Study: 20107296
Drug: Desvenlafaxine succinate
Normalized name: Desvenlafaxine Succinate
DrugBank: Desvenlafaxine (DB06700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desvenlafaxine succinate (DVS) 50-100 mg/day
Study: 16246442
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid (2 g) administration
Study: 16246442
Drug: No ascorbic
Normalized name: ascorbate
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No ascorbic acid administration (control)
Study: 18388877
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg gemfibrozil
Study: 12687332
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg itraconazole (first dose 200 mg)
Study: 12687332
Drug: gemfibrozil alone
Normalized name: Gemfibrozil
DrugBank: Gemfibrozil (DB01241)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: gemfibrozil alone and in combination with itraconazole
Study: 10588314
Drug: Valacyclovir 1000
Normalized name: valacyclovir 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valacyclovir 1000 mg once daily
Study: 21106086
Drug: Valacyclovir 500
Normalized name: valacyclovir 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valacyclovir 500 mg twice daily
Study: 1656713
Drug: ARI treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARI treatment (sorbinil)
Study: 31857319
Drug: Biomarker (AR-V7)
Normalized name: AR-9281
DrugBank: AR-9281 (DB06345)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biomarker (AR-V7) guided clinical treatment
Study: 27120420
Drug: Cognitive Behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behaviour Therapy for Health Anxiety (CBT-HA)
Study: 25417405
Drug: Xinmailong injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xinmailong injection
Study: 22458917
Drug: DDS‐06C (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: DDS‐06C (75 mg tramadol/650 mg paracetamol)
Study: 18628467
Drug: Poxvirus-based PSA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Poxvirus-based PSA vaccine
Study: 18628467
Drug: Vaccine followed
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine followed by Nilutamide
Study: 18628467
Drug: Nilutamide followed
Normalized name: Nilutamide
DrugBank: Nilutamide (DB00665)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nilutamide followed by Vaccine
Study: 18628467
Drug: Vaccine arm
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine arm (Gleason score <7)
Study: 18628467
Drug: Vaccine arm
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine arm (PSA <20 ng/dL)
Study: 18628467
Drug: Vaccine arm
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine arm (prior radiation therapy)
Study: 8018638
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of mifepristone and Placebo
Study: 30320503
Drug: Oral Antidiabetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Antidiabetic Drugs (OAD)
Study: 15677608
Drug: Selegiline augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selegiline augmentation of antipsychotic medication
Study: 13679527
Drug: High-intensity warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-intensity warfarin (INR 3.1 to 4.0)
Study: 13679527
Drug: Moderate-intensity warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-intensity warfarin (INR 2.0 to 3.0)
Study: 15869575
Drug: High-intensity warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-intensity warfarin
Study: 13679527
Drug: Moderate-intensity warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-intensity warfarin
Study: 8122946
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg lovastatin
Study: 7957469
Drug: Bone marrow
Normalized name: bone marrow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone marrow immunoscintigraphy using a 99mTc‐labelled anti‐NCA‐95 monoclonal antibody
Study: 2887726
Drug: Yohimbine (18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yohimbine (18 mg a day)
Study: 30922733
Drug: Capecitabine (1250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine (1250 mg/m2 twice daily on days 1–14 of a 21-day cycle, for eight cycles)
Study: 28554599
Drug: CAM2038 q1w
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAM2038 q1w (7.5, 15, 22.5, and 30mg doses)
Study: 15554568
Drug: Methylphenidate (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (titrated from 0.5 mg/kg per day in week 1 to 1.0 mg/kg per day in week 3)
Study: 11483834
Drug: Intranasal influenza
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal influenza vaccine (1 or 2 doses)
Study: 11483834
Drug: Intranasal influenza
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal influenza vaccine
Study: 9663731
Drug: Psyllium (5.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psyllium (5.1 g b.d.)
Study: 9663731
Drug: Docusate sodium
Normalized name: Docusate Sodium
DrugBank: Docusate (DB11089)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docusate sodium (100 mg b.d.)
Study: 8164599
Drug: Antacid (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacid (40 mmol/day)
Study: 3257375
Drug: Cefamandole 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefamandole 15 mg/kg administered intravenously shortly before cannulation (Group 2)
Study: 3257375
Drug: Cefamandole 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefamandole 30 mg/kg administered intravenously during induction of anesthesia (Group 1)
Study: 31748467
Drug: 420 mg
Normalized name: choline 420 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 420 mg evolocumab every 4 weeks (Q4W)
Study: 31748467
Drug: 140 mg
Normalized name: caffeine 140 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 140 mg evolocumab every 2 weeks (Q2W)
Study: 31748467
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg ezetimibe daily
Study: 30972995
Drug: CSII combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSII combined with sitagliptin treatment (group C)
Study: 30972995
Drug: CSII combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSII combined with acarbose treatment (group B)
Study: 30972995
Drug: CSII treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSII treatment alone (group A)
Study: 28355090
Drug: TX-004HR (4-μg,
Approvals — FDA: no, EMA: no, PMDA: no
Description: TX-004HR (4-μg, 10-μg, and 25-μg doses)
Study: 26344671
Drug: Tocilizumab (TCZ)
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab (TCZ) treatment, intravenous, open-label, assessed over the first 4 months (5 infusions).
Study: 21761206
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg ondansetron 30 min before spinal anesthesia (group II; n=150)
Study: 21761206
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment groups (II, III)
Study: 14966631
Drug: Metronidazole-chlorhexidine solution
Normalized name: chlorhexidine / metronidazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole-chlorhexidine solution
Study: 8384186
Drug: ephedrine/caffeine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: ephedrine/caffeine combination (20mg/200mg)
Study: 1318281
Drug: ephedrine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: ephedrine (20 mg)
Study: 1318281
Drug: caffeine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: caffeine (200 mg)
Study: 31331803
Drug: Guided imagery
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided imagery applied perioperatively (once preoperatively, once on the first postoperative day, twice on the second and third days, totaling six applications)
Study: 31331803
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment and nursing care
Study: 29870922
Drug: Capacitive-resistive electric
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capacitive-resistive electric transfer therapy (Tecar)
Study: 25130297
Drug: Levofloxacin 750
Normalized name: levofloxacin 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin 750 mg IV for 5 days
Study: 25130297
Drug: Levofloxacin 500
Normalized name: levofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin 500 mg IV for 7-14 days
Study: 15899100
Drug: Lumiracoxib 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumiracoxib 100 mg od
Study: 15899100
Drug: Lumiracoxib 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumiracoxib 100 mg od with loading dose of 200 mg od for the first two weeks
Study: 15899100
Drug: Celecoxib 200
Normalized name: celecoxib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 200 mg od
Study: 10086760
Drug: Collaborative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collaborative treatment by primary care physicians (PCPs) and mental health providers (MHPs)
Study: 383417
Drug: PEEP therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEEP therapy (10 patients)
Study: 24720268
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anaesthesia
Study: 26140739
Drug: Allopurinol (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (300 mg/dL)
Study: 21134995
Drug: Simvastatin therapy
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin therapy (20 mg/day, group Ia, n = 15)